Tralokinumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tralokinumab: From Undocumented Original Indication to Diabetic Cataract
One-Sentence Summary
Tralokinumab’s original indication and mechanism of action are not documented in this Evidence Pack, and the drug is currently not marketed in the EU. The TxGNN model predicts it may be effective for Diabetic Cataract, but currently 0 clinical trials and 0 publications support this direction, and the model’s own mechanistic rationale flags the biological link as weak and unvalidated.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license or indication data in Evidence Pack) |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.69% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for Tralokinumab in this Evidence Pack (original_moa: Data Gap), and no original indication is documented. Based on the drug’s known class (an anti-IL-13 monoclonal antibody, as implied by the repurposing rationale text below), a mechanistic link to diabetic cataract cannot be independently confirmed here.
Notably, the evidence pack’s own mechanistic assessment for this top-ranked prediction is unfavorable: diabetic cataract pathology is primarily driven by lens protein glycation, oxidative aggregation, and polyol-pathway activation — not by IL-13-mediated inflammatory signaling. No literature was identified supporting IL-13 blockade as having any effect on lens opacification. The same pattern holds across all 10 predicted indications in this pack (all cataract subtypes plus diabetic retinopathy): each rationale explicitly states the mechanistic connection to IL-13/Th2 immune pathways is weak, unproven, or (in the case of diabetic retinopathy) potentially contradictory, since some literature suggests IL-13 may have an anti-angiogenic rather than pro-pathological role.
Overall, this is a model-driven statistical association without supporting mechanistic or empirical evidence at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No EU marketing authorizations were found. Tralokinumab is currently classified as Not Marketed in this Evidence Pack, with 0 recorded licenses.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA/EMA label warnings and contraindications are flagged as a blocking data gap (DG001) in this Evidence Pack, meaning a formal safety pre-screen (S1) could not yet be performed.)
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is based solely on the TxGNN model (Evidence Level L5, Decision Stage S0) with zero supporting clinical trials or publications, and the model’s own mechanistic rationale assesses the IL-13-to-cataract biological link as weak or unvalidated across all top 10 predicted indications. Combined with the absence of MOA and safety label data, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Tralokinumab (DG002)
- TFDA/EMA label warnings and contraindications to complete the S1 safety pre-screen (DG001, blocking)
- Independent literature or preclinical evidence linking IL-13 inhibition to lens pathology or diabetic cataract progression
- Confirmation of original approved indication(s) to properly assess indication-to-indication mechanistic plausibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.